Diabetic Gastroparesis Pipeline Analysis Demonstrates Novel 6+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

March 15 09:24 2023
Diabetic Gastroparesis Pipeline Analysis Demonstrates Novel 6+ Therapies at the Horizon Expected to Transform the Treatment Paradigm

DelveInsight’s, “Diabetic Gastroparesis Pipeline Insight, 2023,” report provides comprehensive insights about 6+ companies and 8+ pipeline drugs in the Diabetic Gastroparesis pipeline landscape. It covers the Diabetic Gastroparesis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


For Diabetic Gastroparesis Emerging drugs, the Diabetic Gastroparesis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Diabetic Gastroparesis pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.


In the Diabetic Gastroparesis Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Diabetic Gastroparesis clinical trials studies, Diabetic Gastroparesis NDA approvals (if any), and product development activities comprising the technology, Diabetic Gastroparesis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Key takeaways from the Diabetic Gastroparesis Pipeline Report


  • Over 6+ Diabetic Gastroparesis companies are evaluating 8+ Basal Cell Carcinoma pipeline therapies in various stages of development, and their anticipated acceptance in the Diabetic Gastroparesis market would significantly increase market revenue.


  • The leading Diabetic Gastroparesis Companies include Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others.


  • Promising Diabetic Gastroparesis Pipeline Therapies include IW-9179, Metoclopramide Nasal Spray, Reglan ODT, TAK-906 Maleate, CNSA-001, GM-611, RM-131, and others.


  • The Diabetic Gastroparesis Companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Gastroparesis R&D. The Diabetic Gastroparesis pipeline therapies under development are focused on novel approaches to treat/improve Diabetic Gastroparesis.


Request a sample and discover the recent breakthroughs happening in the Diabetic Gastroparesis Pipeline landscape @ Diabetic Gastroparesis Pipeline Outlook Report


Diabetic Gastroparesis Overview

Diabetic Gastroparesis refers to cases of the digestive condition gastroparesis that is caused by diabetes. The symptoms of gastroparesis vary in severity from person to person and may include any combination of the nausea and vomiting, heartburn, loss of appetite, weight loss, bloating, unstable blood sugar levels, gastroesophageal reflux and/or stomach spasms. Gastroparesis is more common in females than males, and in people who have had surgery around the esophagus, stomach, or small intestine, as surgery can affect the vagus nerve.


Diabetic Gastroparesis Emerging Drugs Profile


  • PCS-12852 : Processa Pharmaceuticals

PCS12852 is a novel, potent, and highly selective 5-HT4 receptor agonist for treating Gastrointestinal (GI) mobility disorders. These GI disorders may take many forms, including chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, and gastroparesis. The drug is in Phase II clinical studies for the treatment of Diabetic Gastroparesis.


  • NG101: Neurogastrx

NG101 is a potent, selective and peripherally restricted dopamine D2 receptor antagonist. The drug is in Phase II clinical evaluation for the treatment of Diabetic Gastroparesis. Neurogastrx has generated preclinical data indicating that in addition to its potent antiemetic properties, NG101 is also expected to significantly increase gastric motility, conferring NG101 an ideal pharmacological profile for the treatment of gastroparesis.


For further information, refer to the detailed Diabetic Gastroparesis Drugs Launch, Diabetic Gastroparesis Developmental Activities, and Diabetic Gastroparesis News, click here for Diabetic Gastroparesis Ongoing Clinical Trial Analysis


Diabetic Gastroparesis Pipeline Therapeutics Assessment

There are approx. 6+ key companies which are developing the therapies for Diabetic Gastroparesis. The companies which have their Diabetic Gastroparesis drug candidates in the most advanced stage, i.e. Phase II include, Processa Pharmaceuticals.


Diabetic Gastroparesis Pipeline Segmentation



  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of 
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Route of Administration

  • Oral
  • Parenteral
  • Intravitreal 
  • Subretinal
  • Topical


Molecule Type

  • Monoclonal Antibody
  • Peptides 
  • Polymer 
  • Small molecule
  • Gene therapy


Find out more about the Diabetic Gastroparesis Pipeline Segmentation, Therapeutics Assessment, and Diabetic Gastroparesis Emerging Drugs @ Diabetic Gastroparesis Treatment Landscape


Scope of the Diabetic Gastroparesis Pipeline Report


  • Coverage- Global


  • Diabetic Gastroparesis Companies- Neurogastrx, Vanda Pharmaceuticals, Takeda, Processa Pharmaceuticals, Theravance Biopharma, and others.


  • Diabetic Gastroparesis Pipeline Therapies- IW-9179, Metoclopramide Nasal Spray, Reglan ODT, TAK-906 Maleate, CNSA-001, GM-611, RM-131, and others.


  • Diabetic Gastroparesis Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration


Dive deep into rich insights for drugs for Diabetic Gastroparesis Pipeline Companies and Therapies, click here @ Diabetic Gastroparesis Unmet Needs and Analyst Views


Table of Content

  1. Introduction
  2. Executive Summary
  3. Diabetic gastroparesis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Diabetic gastroparesis – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Diabetic gastroparesis Collaboration Deals
  9. Late Stage Products (Phase III)
  10. Drug Name: Company Name
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. PCS-12852 : Processa Pharmaceuticals
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Diabetic gastroparesis Key Companies
  23. Diabetic gastroparesis Key Products
  24. Diabetic gastroparesis- Unmet Needs
  25. Diabetic gastroparesis- Market Drivers and Barriers
  26. Diabetic gastroparesis- Future Perspectives and Conclusion
  27. Diabetic gastroparesis Analyst Views
  28. Diabetic gastroparesis Key Companies
  29. Appendix


Got Queries? Find out the related information on Diabetic Gastroparesis Mergers and acquisitions, Diabetic Gastroparesis Licensing Activities @ Diabetic Gastroparesis Recent Trends, and Future Perspectives


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/